combined therapy with antihyperglycemic oral agents (metformin, sulfonylureas) and insulin in the management of type 2 diabetic patients (pathogenic substantiation and clinical utility)
Clicks: 299
ID: 148407
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
299 views
57 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #19 of 79 articles by views in Macromolecular rapid communications
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The review deals with the prospect substantiation for using combined therapy by oral antihyperglycemic drugs with different mechanisms of action (metformin + sulfonylureas) and insulin for type 2 diabetes mellitus. The second oral drug is advisable to add, when the average doses of the first drug do not provide full effectiveness, and, since the doses of non-insulin antihyperglycemic drugs are usually not increased to a maximum, the side effects are reduced. Also, a combination of heterogeneous antidiabetic effects within and beyond the glycemic control, which is characteristic of biguanide (metformin), sulfonylurea (glimepiride) and insulin combination, such as reduction of hypoadiponectinemia, dyslipidemia, oxidative stress, inflammation, vascular endothelial cell dysfunction, elimination of «hyperglycemic memory», preservation the phenomenon of ischemic preconditioning, increased pancreatic β-cell survival rate, etc., provides further advantages in the treatment of type 2 diabetes mellitus, as well as in the prevention and treatment of cardiovascular complications.
| Reference Key |
horshunskaia2015mnarodnijcombined
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;M.Yu. Horshunskaia |
| Journal | Macromolecular rapid communications |
| Year | 2015 |
| DOI |
10.22141/2224-0721.4.68.2015.75016
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.